Next Article in Journal
Anti-Osteoporotic Effects of Kukoamine B Isolated from Lycii Radicis Cortex Extract on Osteoblast and Osteoclast Cells and Ovariectomized Osteoporosis Model Mice
Next Article in Special Issue
Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain
Previous Article in Journal
A Structure-Based Drug Discovery Paradigm
Previous Article in Special Issue
Serum Levels of Interleukin-6 and Titers of Antibodies against Porphyromonas gingivalis Could Be Potential Biomarkers for the Diagnosis of Oral Squamous Cell Carcinoma
Open AccessReview

Chemokines in COPD: From Implication to Therapeutic Use

by Pauline Henrot 1,2,3, Renaud Prevel 1,2,3, Patrick Berger 1,2,3 and Isabelle Dupin 1,2,*
1
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33604 Pessac, France
2
INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33604 Pessac, France
3
CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, CIC 1401, F-33604 Pessac, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(11), 2785; https://doi.org/10.3390/ijms20112785
Received: 3 May 2019 / Revised: 3 June 2019 / Accepted: 3 June 2019 / Published: 6 June 2019
(This article belongs to the Special Issue Chemokines in Cancer and Inflammatory Diseases)
Chronic Obstructive Pulmonary Disease (COPD) represents the 3rd leading cause of death in the world. The underlying pathophysiological mechanisms have been the focus of extensive research in the past. The lung has a complex architecture, where structural cells interact continuously with immune cells that infiltrate into the pulmonary tissue. Both types of cells express chemokines and chemokine receptors, making them sensitive to modifications of concentration gradients. Cigarette smoke exposure and recurrent exacerbations, directly and indirectly, impact the expression of chemokines and chemokine receptors. Here, we provide an overview of the evidence regarding chemokines involvement in COPD, and we hypothesize that a dysregulation of this tightly regulated system is critical in COPD evolution, both at a stable state and during exacerbations. Targeting chemokines and chemokine receptors could be highly attractive as a mean to control both chronic inflammation and bronchial remodeling. We present a special focus on the CXCL8-CXCR1/2, CXCL9/10/11-CXCR3, CCL2-CCR2, and CXCL12-CXCR4 axes that seem particularly involved in the disease pathophysiology. View Full-Text
Keywords: COPD; chemokines; exacerbation; airway remodeling; chronic inflammation; gradient; biomarker COPD; chemokines; exacerbation; airway remodeling; chronic inflammation; gradient; biomarker
Show Figures

Graphical abstract

MDPI and ACS Style

Henrot, P.; Prevel, R.; Berger, P.; Dupin, I. Chemokines in COPD: From Implication to Therapeutic Use. Int. J. Mol. Sci. 2019, 20, 2785.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop